Global Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The global lung cancer diagnostics market is projected to register a substantial CAGR of 14.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

Global Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of the Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global lung cancer diagnostics market are:

Increase in research in the field of lung cancer diagnosis and development

Rise in prevalence and incidence of lung cancer in the world

Market Players:

Some of the major players operating in the global lung cancer diagnostics market are:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific Inc.

Abbott

Quest Diagnostics Incorporated

Biodesix

Amoy Diagnostics Co., Ltd.

Bio-Rad Laboratories, Inc.

Biocartis

Boditech Med Inc.

Danaher

Vela Diagnostics

DiaSorin S.p.A.

Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)

20/20 Gene Systems

Guardant Health, Inc.

Inivata Ltd.

LalPathLabs.com

LungLife AI, Inc.

MedGenome

Myriad Genetics, Inc.

NeoGenomics Laboratories

NanoString

Nanoentek

Oncocyte Corporation

PerkinElmer Inc.

PlexBio

QIAGEN

Siemens Healthcare GmbH

Veracyte, Inc.

1 INTRODUCTION 53

1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF GLOBAL LUNG CANCER DIAGNOSTICS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 55

2 MARKET SEGMENTATION 58

2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT TYPE LIFELINE CURVE 64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET TESTING TYPE COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71

3 EXECUTIVE SUMMARY 72

4 PREMIUM INSIGHTS 75

4.1 PORTER'S FIVE FORCES 78
4.2 PESTEL ANALYSIS 79
4.3 INDUSTRY INSIGHTS 80

5 EPIDERMIOLOGY 81

6 REGULATIONS 82

7 MARKET OVERVIEW 85

7.1 DRIVERS 87
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 87
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 88
- 7.1.3 INCREASING CASES OF LUNG CANCER 90
- 7.1.4 RISE IN PRODUCT APPROVALS 90
7.2 RESTRAINTS 92
- 7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 92
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 92
7.3 OPPORTUNITIES 94
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 94
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 94
- 7.3.3 RISING AWARENESS OF LUNG CANCER 95
7.4 CHALLENGES 96
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 96
- 7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 96
- 7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 97

8 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 98

8.1 OVERVIEW 99
8.2 INSTRUMENTS 102
- 8.2.1 IMAGING INSTRUMENTS 103
  - 8.2.1.1 CT SYSTEMS 103
  - 8.2.1.2 ULTRASOUND SYSTEMS 103
  - 8.2.1.3 MRI SYSTEMS 103
  - 8.2.1.4 OTHERS 103
- 8.2.2 BIOPSY INSTRUMENTS 104
  - 8.2.2.1 NEEDLE BIOPSY 104
  - 8.2.2.2 ENDOSCOPIC BIOPSY 104
  - 8.2.2.3 CORE BIOPSY 104
  - 8.2.2.4 OTHERS 104
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 105
  - 8.2.3.1 SLIDE STAINING SYSTEMS 105
  - 8.2.3.2 TISSUE PROCESSING SYSTEMS 105
  - 8.2.3.3 CELL PROCESSORS 105
  - 8.2.3.4 PCR INSTRUMENTS 105
  - 8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 105
8.3 CONSUMABLES AND ACCESSORIES 106
- 8.3.1 KITS 107
  - 8.3.1.1 DNA POLYMERASE KITS 107
  - 8.3.1.2 NUCLEIC ACID ISOLATION KITS 107
  - 8.3.1.3 PCR KITS 107
  - 8.3.1.4 OTHERS 107
- 8.3.2 REAGENTS 108
  - 8.3.2.1 ASSAYS 108
  - 8.3.2.2 BUFFERS 108
  - 8.3.2.3 PRIMERS 108
  - 8.3.2.4 OTHERS 108
- 8.3.3 PROBES 109
- 8.3.4 OTHER CONSUMABLES 109

9 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 110

9.1 OVERVIEW 111
9.2 IMAGING TEST 114
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
- 9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 115
- 9.2.3 CHEST X-RAY 115
- 9.2.4 BONE SCAN 115
- 9.2.5 MRI 115
- 9.2.6 OTHERS 115
9.3 BIOMARKERS TEST 116
- 9.3.1 EGFR MUTATION TEST 117
- 9.3.2 KRAS MUTATION TEST 117
- 9.3.3 ALK TEST 117
- 9.3.4 HER2 TEST 117
- 9.3.5 OTHERS 118
9.4 BIOPSY 118
- 9.4.1 NEEDLE BIOPSY 119
- 9.4.2 BRONCHOSCOPY BIOPSY 119
- 9.4.3 CORE BIOPSY 119
- 9.4.4 OTHERS 119
9.5 BLOOD TEST 119
- 9.5.1 COMPLETE BLOOD COUNT (CBC) 120
- 9.5.2 BLOOD CHEMISTRY TESTS 120
- 9.5.3 OTHERS 120
9.6 OTHERS 121

10 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 122

10.1 OVERVIEW 123
10.2 NON-SMALL CELL LUNG CANCER 126
10.3 SMALL CELL LUNG CANCER 127

11 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY END USER 128

11.1 OVERVIEW 129
11.2 HOSPITAL 132
11.3 ASSOCIATED LABS 132
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 133
11.5 DIAGNOSTIC IMAGING CENTERS 134
11.6 CANCER RESEARCH INSTITUTES 134
11.7 OTHERS 135

12 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 136

12.1 OVERVIEW 137
12.2 DIRECT TENDER 140
12.3 RETAIL SALES 141

13 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY REGION 142

13.1 OVERVIEW 143
13.2 NORTH AMERICA 148
- 13.2.1 U.S. 157
- 13.2.2 CANADA 162
- 13.2.3 MEXICO 167
13.3 EUROPE 172
- 13.3.1 GERMANY 182
- 13.3.2 U.K. 187
- 13.3.3 FRANCE 192
- 13.3.4 ITALY 197
- 13.3.5 SPAIN 202
- 13.3.6 RUSSIA 207
- 13.3.7 NETHERLANDS 212
- 13.3.8 SWITZERLAND 217
- 13.3.9 TURKEY 222
- 13.3.10 BELGIUM 227
- 13.3.11 POLAND 232
- 13.3.12 DENMARK 237
- 13.3.13 SWEDEN 242
- 13.3.14 NORWAY 247
- 13.3.15 FINLAND 252
- 13.3.16 REST OF EUROPE 257
13.4 ASIA-PACIFIC 258
- 13.4.1 CHINA 268
- 13.4.2 JAPAN 273
- 13.4.3 SOUTH KOREA 278
- 13.4.4 AUSTRALIA 283
- 13.4.5 INDIA 288
- 13.4.6 SINGAPORE 293
- 13.4.7 INDONESIA 298
- 13.4.8 PHILIPPINES 303
- 13.4.9 VIETNAM 308
- 13.4.10 MALAYSIA 313
- 13.4.11 THAILAND 318
- 13.4.12 NEW ZEALAND 323
- 13.4.13 TAIWAN 328
- 13.4.14 REST OF ASIA-PACIFIC 333
13.5 SOUTH AMERICA 334
- 13.5.1 BRAZIL 343
- 13.5.2 ARGENTINA 348
- 13.5.3 REST OF SOUTH AMERICA 353
13.6 MIDDLE EAST AND AFRICA 354
- 13.6.1 SOUTH AFRICA 364
- 13.6.2 EGYPT 369
- 13.6.3 SAUDI ARABIA 374
- 13.6.4 U.A.E. 379
- 13.6.5 KUWAIT 384
- 13.6.6 OMAN 389
- 13.6.7 BAHRAIN 394
- 13.6.8 QATAR 399
- 13.6.9 REST OF MIDDLE EAST AND AFRICA 404

14 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 405

14.1 COMPANY SHARE ANALYSIS: GLOBAL 405
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 406
14.3 COMPANY SHARE ANALYSIS: EUROPE 407
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 408

15 SWOT ANALYSIS 409

16 COMPANY PROFILE 410

16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 410
- 16.1.1 COMPANY SNAPSHOT 410
- 16.1.2 REVENUE ANALYSIS 410
- 16.1.3 COMPANY SHARE ANALYSIS 411
- 16.1.4 PRODUCT PORTFOLIO 411
- 16.1.5 RECENT DEVELOPMENTS 411
16.2 THERMO FISHER SCIENTIFIC INC. (2022) 412
- 16.2.1 COMPANY SNAPSHOT 412
- 16.2.2 REVENUE ANALYSIS 412
- 16.2.3 COMPANY SHARE ANALYSIS 413
- 16.2.4 PRODUCT PORTFOLIO 413
- 16.2.5 RECENT DEVELOPMENTS 413
16.3 ABBOTT (2022) 414
- 16.3.1 COMPANY SNAPSHOT 414
- 16.3.2 REVENUE ANALYSIS 414
- 16.3.3 COMPANY SHARE ANALYSIS 415
- 16.3.4 PRODUCT PORTFOLIO 415
- 16.3.5 RECENT DEVELOPMENTS 415
16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 416
- 16.4.1 COMPANY SNAPSHOT 416
- 16.4.2 REVENUE ANALYSIS 416
- 16.4.3 COMPANY SHARE ANALYSIS 417
- 16.4.4 PRODUCT PORTFOLIO 417
- 16.4.5 RECENT DEVELOPMENTS 419
16.5 BIODESIX (2022) 420
- 16.5.1 COMPANY PROFILE 420
- 16.5.2 REVENUE ANALYSIS 420
- 16.5.3 COMPANY SHARE ANALYSIS 421
- 16.5.4 PRODUCT PORTFOLIO 421
- 16.5.5 RECENT DEVELOPMENTS 421
16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 422
- 16.6.1 COMPANY SNAPSHOT 422
- 16.6.2 PRODUCT PORTFOLIO 422
- 16.6.3 RECENT DEVELOPMENTS 422
16.7 BIO-RAD LABORATORIES, INC. (2022) 423
- 16.7.1 COMPANY SNAPSHOT 423
- 16.7.2 REVENUE ANALYSIS 423
- 16.7.3 PRODUCT PORTFOLIO 424
- 16.7.4 RECENT DEVELOPMENTS 424
16.8 BIOCARTIS (2022) 425
- 16.8.1 COMPANY SNAPSHOT 425
- 16.8.2 REVENUE ANALYSIS 425
- 16.8.3 PRODUCT PORTFOLIO 426
- 16.8.4 RECENT DEVELOPMENTS 426
16.9 BODITECH MED INC. 427
- 16.9.1 COMPANY PROFILE 427
- 16.9.2 PRODUCT PORTFOLIO 427
- 16.9.3 RECENT DEVELOPMENTS 427
16.10 DANAHER (2022) 428
- 16.10.1 COMPANY SNAPSHOT 428
- 16.10.2 REVENUE ANALYSIS 428
- 16.10.3 PRODUCT PORTFOLIO 429
- 16.10.4 RECENT DEVELOPMENTS 429
16.11 DIASORIN S.P.A. (2022) 430
- 16.11.1 COMPANY SNAPSHOT 430
- 16.11.2 REVENUE ANALYSIS 430
- 16.11.3 PRODUCT PORTFOLIO 431
- 16.11.4 RECENT DEVELOPMENTS 431
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 432
- 16.12.1 COMPANY SNAPSHOT 432
- 16.12.2 REVENUE ANALYSIS 432
- 16.12.3 PRODUCT PORTFOLIO 433
- 16.12.4 RECENT DEVELOPMENTS 433
16.13 20/20 GENE SYSTEMS 434
- 16.13.1 COMPANY PROFILE 434
- 16.13.2 PRODUCT PORTFOLIO 434
- 16.13.3 RECENT DEVELOPMENTS 434
16.14 GUARDANT HEALTH INC. 435
- 16.14.1 COMPANY PROFILE 435
- 16.14.2 PRODUCT PORTFOLIO 435
- 16.14.3 RECENT DEVELOPMENTS 435
16.15 INIVATA LTD. 436
- 16.15.1 COMPANY PROFILE 436
- 16.15.2 PRODUCT PORTFOLIO 436
- 16.15.3 RECENT DEVELOPMENTS 436

16.16 LALPATHLABS.COM (2022) 437
- 16.16.1 COMPANY SNAPSHOT 437
- 16.16.2 REVENUE ANALYSIS 437
- 16.16.3 PRODUCT PORTFOLIO 438
- 16.16.4 RECENT DEVELOPMENTS 439
16.17 LUNGLIFE AI, INC. (2022) 440
- 16.17.1 COMPANY SNAPSHOT 440
- 16.17.2 PRODUCT PORTFOLIO 440
- 16.17.3 RECENT DEVELOPMENTS 440
16.18 MEDGENOME 441
- 16.18.1 COMPANY SNAPSHOT 441
- 16.18.2 PRODUCT PORTFOLIO 441
- 16.18.3 RECENT DEVELOPMENTS 442
16.19 MYRIAD GENETICS, INC. 443
- 16.19.1 COMPANY SNAPSHOT 443
- 16.19.2 PRODUCT PORTFOLIO 443
- 16.19.3 RECENT DEVELOPMENTS 443
16.20 NEOGENOMICS LABORATORIES (2022) 444
- 16.20.1 COMPANY SNAPSHOT 444
- 16.20.2 REVENUE ANALYSIS 444
- 16.20.3 PRODUCT PORTFOLIO 445
- 16.20.4 RECENT DEVELOPMENTS 445
16.21 NANOSTRING (2022) 446
- 16.21.1 COMPANY SNAPSHOT 446
- 16.21.2 REVENUE ANALYSIS 446
- 16.21.3 PRODUCT PORTFOLIO 447
- 16.21.4 RECENT DEVELOPMENTS 447
16.22 NANOENTEK 448
- 16.22.1 COMPANY PROFILE 448
- 16.22.2 PRODUCT PORTFOLIO 448
- 16.22.3 RECENT DEVELOPMENTS 448
16.23 ONCOCYTE CORPORATION 449
- 16.23.1 COMPANY PROFILE 449
- 16.23.2 SERVICE PORTFOLIO 449
- 16.23.3 RECENT DEVELOPMENTS 449
16.24 PERKINELMER INC 450
- 16.24.1 COMPANY PROFILE 450
- 16.24.2 REVENUE ANALYSIS 450
- 16.24.3 PRODUCT PORTFOLIO 451
- 16.24.4 RECENT DEVELOPMENTS 451
16.25 PLEXBIO 452
- 16.25.1 COMPANY SNAPSHOT 452
- 16.25.2 PRODUCT PORTFOLIO 452
- 16.25.3 RECENT DEVELOPMENTS 452
16.26 QIAGEN 453
- 16.26.1 COMPANY SNAPSHOT 453
- 16.26.2 REVENUE ANALYSIS 453
- 16.26.3 PRODUCT PORTFOLIO 454
- 16.26.4 RECENT DEVELOPMENTS 454
16.27 SIEMENS HEALTHCARE GMBH 455
- 16.27.1 COMPANY SNAPSHOT 455
- 16.27.2 REVENUE ANALYSIS 455
- 16.27.3 PRODUCT PORTFOLIO 456
- 16.27.4 RECENT DEVELOPMENTS 456
16.28 VERACYTE, INC. (2022) 457
- 16.28.1 COMPANY SNAPSHOT 457
- 16.28.2 REVENUE ANALYSIS 457
- 16.28.3 PRODUCT PORTFOLIO 458
- 16.28.4 RECENT DEVELOPMENTS 458
16.29 VELA DIAGNOSTICS 459
- 16.29.1 COMPANY PROFILE 459
- 16.29.2 PRODUCT PORTFOLIO 459
- 16.29.3 RECENT DEVELOPMENTS 461

17 QUESTIONNAIRE 462

18 RELATED REPORTS 465

LIST OF FIGURES

FIGURE 1 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 58
FIGURE 2 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 61
FIGURE 3 GLOBAL LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 62
FIGURE 4 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 63
FIGURE 5 GLOBAL LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 63
FIGURE 6 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 66
FIGURE 7 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 67
FIGURE 8 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 69
FIGURE 9 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 70
FIGURE 10 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION 74
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE GLOBAL LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 75
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030 75
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LUNG CANCER DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 76
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL LUNG CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD 77
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL LUNG CANCER DIAGNOSTICS MARKET 86
FIGURE 16 THE GLOBAL MORTALITY RATE DUE TO CANCER 89
FIGURE 17 THE DATA GIVEN BELOW SHOWS THE INCREASING GLOBAL CANCER RATE IN 2020 89
FIGURE 18 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT 92
FIGURE 19 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 99
FIGURE 20 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 100
FIGURE 21 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 100
FIGURE 22 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 101
FIGURE 23 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 111
FIGURE 24 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 112
FIGURE 25 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 112
FIGURE 26 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 113
FIGURE 27 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 123
FIGURE 28 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 124
FIGURE 29 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 124
FIGURE 30 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 125
FIGURE 31 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022 129
FIGURE 32 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 130
FIGURE 33 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 130
FIGURE 34 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 131
FIGURE 35 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 137
FIGURE 36 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 138
FIGURE 37 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 138
FIGURE 38 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 139
FIGURE 39 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 144
FIGURE 40 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY REGION (2022) 145
FIGURE 41 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 145
FIGURE 42 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 146
FIGURE 43 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023 & 2030) 146
FIGURE 44 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 149
FIGURE 45 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 150
FIGURE 46 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 150
FIGURE 47 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 151
FIGURE 48 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 151
FIGURE 49 EUROPE LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 173
FIGURE 50 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 174
FIGURE 51 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 174
FIGURE 52 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 175
FIGURE 53 EUROPE LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 175
FIGURE 54 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 259
FIGURE 55 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 260
FIGURE 56 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 260
FIGURE 57 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 261
FIGURE 58 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 261
FIGURE 59 SOUTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 335
FIGURE 60 SOUTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 336
FIGURE 61 SOUTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2030) 336
FIGURE 62 SOUTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2030) 337
FIGURE 63 SOUTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2021-2030) 337
FIGURE 64 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 355
FIGURE 65 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 356
FIGURE 66 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 356
FIGURE 67 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 357
FIGURE 68 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 357
FIGURE 69 GLOBAL LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 405
FIGURE 70 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 406
FIGURE 71 EUROPE LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 407
FIGURE 72 ASIA-PACIFIC LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 408